Skip to main content
Log in

Radioimmunotherapy with alpha-emitting nuclides

  • Review article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract.

This review discusses the application of alpha particle-emitting radionuclides in targeted radioimmunotherapy. It will outline the production and chemistry of astatine-211, bismuth-212, lead-212, actinium-225, bismuth-213, fermium-255, radium-223 and terbium-149, which at present are the most promising alpha-emitting isotopes available for human clinical use. The selective cytotoxicity offered by alpha particle-emitting radioimmunoconstructs is due to the high linear energy transfer and short particle path length of these radionuclides. Based upon the pharmacokinetics of alpha particle-emitting radioimmunoconstructs, both stochastic and conventional dosimetric methodology is discussed, as is the preclinical and initial clinical use of these radionuclides conjugated to monoclonal antibodies for the treatment of human neoplasia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

McDevitt, M., Sgouros, G., Finn, R. et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25, 1341–1351 (1998). https://doi.org/10.1007/s002590050306

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002590050306

Navigation